Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03439293 · ClinicalTrials.gov registry record · Phase 2
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03439293 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 61 participants.
The verdict
NCT03439293, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2018-03-13 |
| Est. Completion | 2023-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03439293
The ClinicalTrials.gov registry entry for NCT03439293 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03439293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03439293 about?
NCT03439293 is a clinical study titled "A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)". The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.
What is the current status of trial NCT03439293?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2018-03-13. Estimated completion is 2023-06-26.
What interventions are being tested in trial NCT03439293?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT03439293?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.